close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bausch + Lomb Corporation

< Previous 1 2 3 Next >
Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Ophthalmology Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Release Third-Quarter 2023 Financial Results on November 1
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Completes Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches LUMIFY EYE ILLUMINATIONS™ in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb’s ONE by ONE and Biotrue® Eye Care Recycling Programs Recognized As Sustainability Service of the Year Award Winners
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Pricing of Senior Secured Notes Offering
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Disclosure of Historical and Pro Forma Financial Information With Respect to Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Present New Scientific Data on its Surgical Products and Pipeline at European Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Participate at the 2023 Wells Fargo Healthcare Conference
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Second-Quarter 2023 Results and Raises Full-Year 2023 Revenue Outlook
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Solidifies Leadership Team
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Release Second-Quarter 2023 Financial Results on August 2
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Will Acquire XIIDRA®
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches PreserVision® AREDS 2 Formula Soft Gels Plus CoQ10 in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceutical Products Will Be Presented During American Optometric Association's Optometry's Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches Biotrue® Hydration Boost Contact Lens Rehydrating Drops in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Launches Bausch + Lomb INFUSE® Multifocal Silicone Hydrogel Contact Lenses in the United States
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces Key Leadership Changes
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ (Perfluorohexyloctane Ophthalmic Solution) for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
From Bausch + Lomb Corporation
Via Business Wire
Tickers BLCO TSX:BLCO
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today